ESSA Pharma Inc
EPIX
View Detailed Chart
0.211USD
+0.001+0.62%
Close 09/19, 16:00（ET）Quotes delayed by 15 min
9.37MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+0.62%
5 Days
+4.09%
1 Month
-88.94%
6 Months
-86.80%
Year to Date
-88.20%
1 Year
-96.74%
View Detailed Chart
TradingKey Stock Score
Currency: USD Updated: 2025-09-19Key Insights
Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a . The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
0
analysts
--
Current Rating
1.700
Target Price
+709.91%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
ESSA Pharma Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is focused on developing proprietary therapies for the treatment of patients with prostate cancer. Its lead candidate, Masofaniten (formerly EPI-7386), is an oral, small molecule that inhibits the N-terminal domain of the androgen receptor (AR). Masofaniten is in development in combination with antiandrogen treatments in patients with prostate cancer who are earlier in their course of the disease. The Company is completing the clinical development of masofaniten as a monotherapy treatment for patients with metastatic castration-resistant prostate cancer (mCRPC).
Overvalued
The company’s latest PE is -0.37, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 32.28M shares, decreasing 36.10% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 15.75.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Company
ESSA Pharma Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is focused on developing proprietary therapies for the treatment of patients with prostate cancer. Its lead candidate, Masofaniten (formerly EPI-7386), is an oral, small molecule that inhibits the N-terminal domain of the androgen receptor (AR). Masofaniten is in development in combination with antiandrogen treatments in patients with prostate cancer who are earlier in their course of the disease. The Company is completing the clinical development of masofaniten as a monotherapy treatment for patients with metastatic castration-resistant prostate cancer (mCRPC).
Ticker SymbolEPIX
CompanyESSA Pharma Inc
CEODr. David Ross Parkinson, M.D.
Websitehttps://www.essapharma.com/
Related Instruments
-2.25%
0.00%
-2.81%
-1.37%
0.00%
-0.09%
-2.59%
+0.10%
+0.89%
+0.10%
0.00%
+5.47%
+0.14%
0.00%
0.00%
+0.19%
0.00%
-0.24%
+0.29%
+0.05%
